Neuroendocrine tumors of the gastrointestinal tract are a rare and heterogenous group of neoplasms that posses certain common cellular characteristics and unique characteristics depending on their location within the gastrointestinal tract. They present with a wide variety of symptoms including abdominal pain, nausea, vomiting, constipation, red or black discoloration of the stool, skin redness, fatigue, inexplicable weight loss, jaundice, skin scabbing and mental disturbances. The clinical presentation of neuroendocrine tumors of the gastrointestinal tract differs depending on the location of the gastrointestinal tract where the tumor forms, how expansive their local growth is at the site of formation, if they secrete hormones into the organism of the patient and if they do, which particular hormone they secrete and whether there are distant meastases present. The early diagnosis of all neoplasms, including neuroendocrine tumors of the gastrointestinal tract is paramount since it decreases unfavorable outcomes for the patient. Along with a clinical exam and history taking, the diagnosis of neuroendocrine tumors of the gastrointestinal tract is comprised of laboratory examinations of the levels of chemical compunds which these neoplasms may secrete along with radiological imaging and pathohistological analysis of the neoplasm following a biopsy. The prognosis and treatment of neuroendocrine tumors of the gastrointestinal tract depends on which stage the disease is in, which in turn is determined using the World Health Organization guidelines from 2019. Methods of treatment include surgical resection of the part of the gastrointestinal tract where the neoplasm is located, chemotherapy and radiotherapy, somatostatin analogues, imunotherapy and radionuclide therapy of peptide receptors.